Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke
about
Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic strokeActivated protein C: A regulator of human skin epidermal keratinocyte functionCytoprotective-selective activated protein C therapy for ischaemic strokeSelecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection.Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteersActivated protein C: biased for translation.Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's diseaseActivated protein C promotes neuroprotection: mechanisms and translation to the clinic.An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway.Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.Down-regulation of the clotting cascade by the protein C pathwayInvestigational anticoagulants for hematological conditions: a new generation of therapies.2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.3K3A-activated protein C stimulates postischemic neuronal repair by human neural stem cells in mice.Gain in translation: heme oxygenase-1 induced by activated protein C promotes thrombus resolution.Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity.Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C.Factor VIIa induces anti-inflammatory signaling via EPCR and PAR1.
P2860
Q26782990-8374F9CC-A030-47A2-ADB8-93D738E7D53FQ26830499-69FE46CF-7586-4B36-BFE4-D292DB452ED2Q27009122-836C8D41-FAF8-44A8-95B0-A905D16D2A5EQ30275531-32699959-9CF6-43E5-9517-BF734419F6C8Q33693490-09530910-D526-4F4F-B52C-DC5AC9A0F1F8Q35583397-77267651-6F1D-4F03-8ED2-B8D81A0BA30BQ36736442-A281BABB-717A-47CA-B1A5-022A71C08B11Q36767796-B3AD4919-47E5-4F89-8C45-B9DB738A19C7Q36997361-E5DBF0AB-FBAA-45C4-B8DD-9F7A91F44ED4Q37000469-1E1C9BB4-CCD5-43A6-BF2C-08B71B6BE5BAQ37085780-4A616720-A813-45F3-98A1-4957320E3DCFQ37552150-7BF43E3A-7A48-4009-A680-C32B12C0AF8BQ37701081-10E8BF61-59CF-4F52-AA38-B2704C9AD718Q38123237-F2ED9E10-0B9A-4936-BBEE-2A4BD9F58C5AQ38985138-E7AAD36E-5A71-4F57-B4B0-941850A45223Q40826783-9B61098A-203C-483C-BB66-A979CA16E356Q40843809-EABA83D9-5743-4D6E-86A2-016C10A37583Q42246927-C0C38606-DB10-43A2-AAD3-2720B39EA542Q46037752-338ED874-132F-41F4-8877-DD34E6E14A4EQ52316878-C0379860-84EC-4D49-8D62-DFEED25021A9
P2860
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Preclinical safety and pharmac ...... protein C for ischemic stroke
@ast
Preclinical safety and pharmac ...... protein C for ischemic stroke
@en
type
label
Preclinical safety and pharmac ...... protein C for ischemic stroke
@ast
Preclinical safety and pharmac ...... protein C for ischemic stroke
@en
prefLabel
Preclinical safety and pharmac ...... protein C for ischemic stroke
@ast
Preclinical safety and pharmac ...... protein C for ischemic stroke
@en
P2093
P2860
P1476
Preclinical safety and pharmac ...... protein C for ischemic stroke
@en
P2093
Berislav V Zlokovic
Kent E Pryor
Patricia D Williams
Thomas P Davis
P2860
P304
P356
10.2174/138161212802430413
P577
2012-01-01T00:00:00Z